ReviewAtherosclerosis2021
Coronavirus disease-19: The multi-level, multi-faceted vasculopathy.
Review in Atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis.Seminars in arthritis and rheumatism · 2022Pooled it
- Endothelial cells modulate immune cell responses during atherosclerosis.Trends in immunology · 2026Review
- Observational
- Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives.Annals of medicine and surgery (2012) · 2024Review
- Symptom burden, coagulopathy and heart disease after acute SARS-CoV-2 infection in primary practice.Scientific reports · 2024Observational
- Immunoglobulin A vasculitis: The clinical features and pathophysiology.The Kaohsiung journal of medical sciences · 2024Review
- Evaluation of blood pressure variation in recovered COVID-19 patients at one-year follow-up: a retrospective cohort study.BMC cardiovascular disorders · 2024Article
- [Research advances in the etiology and pathogenesis of immunoglobulin A vasculitis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Review
- Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?Neurology international · 2023Review
- Cogan syndrome following SARS-COV-2 infection.Clinical rheumatology · 2023Article
- Article
- Marked elevations in lung and plasma ceramide in COVID-19 linked to microvascular injury.JCI insight · 2023Article
- Intestinal barrier dysfunction as a key driver of severe COVID-19.World journal of virology · 2023Review
- Review
- Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care.Medicina (Kaunas, Lithuania) · 2022Review
- Air leaks in COVID-19.World journal of virology · 2022Review
- Review
- Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies.EBioMedicine · 2022Article
- Severe stroke in patients admitted to intensive care unit after COVID-19 infection: Pictorial essay of a case series.Brain hemorrhages · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe new coronavirus disease (COVID-19) is a systemic disease. Mounting evidence depict signs and symptoms involving multiple organs, most of which supported by pathological data. A plausible link to these manifestations is vascular and endothelial dysfunction/damage. However, much of the current knowledge relies on opinion and incipient evidence. We aim to objectively appraise current evidence on the association between COVID-19 and vascular disease, specifically endotheliitis and vasculitis.
methodsTwo researchers independently entered the search terms COVID-19 OR SARS-CoV-2 AND vasculitis, endotheliitis OR endothelium in the following online platforms: MedRxiv and LitCovid (PubMed). The search period was set from November 1, 2019 to August 28, 2020. Manuscripts with unavailable full texts, not in English, mainly on pre-clinical data, presenting only study designs or not directly related to the topics of this review were excluded. Retrospective and prospective studies, especially longitudinal ones, were given priority to the purpose of this review. Since there was paucity of prospective controlled evidence, case reports/series were also considered.
resultsA total of 318 manuscripts were initially found. Sixty-seven (21%) were excluded: 59 (18.5%) met exclusion criteria and 8 (2.5%) were duplicates. One hundred and forty-two manuscripts (44,6%) did not provide original data and were also excluded: 35 (11%) were comments, 108 (33.9%) reviews; 1 (0.3%) position paper. One hundred and seven (33.6%) studies were considered for the present scoping review: 81 (25,5%) case reports/series; 18 (5.7%) prospective; 8 (2.5%) retrospective. Viral inclusions in endothelial cells, mononuclear cell infiltrates in the intima of small vessels and markers of endothelial cell apoptosis were demonstrated. Specificities of COVID-19 may lead to diverse vascular manifestations in different levels of the vascular bed.
conclusionsEvidence indicates that COVID-19 targets vasculature and endothelium. However, high quality data is still lacking and studies with prospective designs and appropriately matched controls are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.